Global Retinal Vein Occlusion (RVO) Market - 2024-2032

The global retinal vein occlusion (RVO) market reached US$ 856.37 million in 2023 and is expected to reach US$ 1,913.81 million by 2032, growing at a CAGR of 9.4% during the forecast period 2024-2032.

Retinal vein occlusion is the blockage of small veins that transport blood away from the retina a major part of the eye which converts light images into nerve signals and sends them to the brain. Retinal vein occlusion is primarily caused by atherosclerosis, where hardened arteries form blood clots. Retinal vein occlusion (RVO) is the second most common retinal vascular disease and is a common loss of vision in older patients. There are two types of RVO: branch retinal vein occlusion (BRVO) and central retinal vein occlusion (CRVO). Central retinal vein occlusion is an occlusion of the main retinal vein posterior to the lamina cribrosa of the optic nerve and is typically caused by thrombosis.

Market Dynamics: Drivers & Restraints

Rising prevalence of retinal vein occlusion

The global disease burden of retinal vein occlusion (RVO) is rising due to the aging population and increased prevalence of risk factors such as cardiovascular diseases and obesity. Age is a serious risk factor for retinal vein occlusion, a retrospective study published in the Journal of Opthalmology Retina in February 2022 has stated that retinal vein occlusion is highly prevalent among people aged 65 to 85 years. Among the population subtypes, 65 to 85 years old composed 70.3% of RVO cases followed by the 45 to 65 age group accounting for 24.3% of cases, the 25 to 45 age group accounting for 2.7% of cases, above 85 age group representing 2.2% of cases, and below 25 age group representing 0.5% of total cases.

This signifies that with age, the incidence of retinal vein occlusion (RVO) rises. As the global population is aging, especially in the Asia-Pacific region, the number of retinal vein occlusion (RVO) cases is expected to surge in the forecasted period, creating a demand for advanced therapies, and also increasing the adoption rate of existing treatments.

The high cost of treatment can be a significant barrier to retinal vein occlusion (RVO) market growth.

Anti-VEGF drugs are considered the gold standard for the treatment of patients with retinal vein occlusion (RVO). However, these drugs are often expensive, as multiple administrations are required to improve the patient's vision and improve their quality of life. Due to the cost barrier, the adoption rates may be low in certain low-to-middle-income countries where the patients don't have proper insurance coverage.

For instance, the incidence of retinal vein occlusion is high in the Asia-Pacific region, where the majority of the global elderly population resides. The majority of the Asia-Pacific countries are middle-income countries and the population lacks health insurance. For instance, in the Philippines, the cost of 1 vial of Eylea (Aflibercept) can cost up to ₱ 60,000.00 (US$ 1,000). This can be a significant economic burden to patients in the country.

Segment Analysis

The global Retinal vein occlusion (RVO) market is segmented based on type, treatment, and region.

Anti-vascular endothelial growth factor (Anti-VEGF) drugs are dominating the treatment type segment with the highest market share.

Vascular endothelial growth factor (VEGF) is a protein produced in the body, that promotes vasculature growth. This growth in blood vessels plays a crucial role in physiological processes such as embryogenesis, skeletal growth, and reproductive functions. However, VEGF is also involved in the pathogenesis of certain diseases such as tumor growth, neovascularization of the eye, etc. In retinal vein occlusion (RVO), vascular endothelial growth factor plays a crucial role in increasing vascular permeability, inflammation, and abnormal blood vessel growth. This abnormal growth may cause ischemia in the vein that drains the blood from the retina.

Anti-VEGF drugs inhibit the vascular endothelial growth factor thereby reducing macular edema, restoring the blood flow, and improving vision. The currently approved anti-vascular endothelial growth factor (Anti-VEGF) drugs are ranibizumab, aflibercept, and faricimab. In addition to these drugs, although not approved, bevacizumab is widely used off-label. Several clinical studies have reported the therapeutic efficiency of anti-VEGF drugs in retinal vein occlusion (RVO) and have labeled them as gold-standard therapies.

For instance, a meta-analysis study published in Springer Nature Journals in March 2024, has stated that anti-VEGF drugs have evolved as a standard of care option in retinal vein occlusion treatment as they have been proven to inhibit vascular leakage and effectively improve and maintain vision.

Geographical Analysis

North America is expected to hold a significant share of the Retinal vein occlusion (RVO) market.

North America is estimated to hold the highest market share throughout the forecast period, owing to factors like highly regulated and well-developed healthcare infrastructure. The growing collective efforts of key players to improve their product portfolios and ensure high-quality standards are expected to boost the demand for RVO treatment across this region. The increasing prevalence of retinal vein occlusion (RVO) is estimated to be a major factor influencing market growth in the region.

For instance, in January 2024, Genentech, Inc. a subsidiary of F. Hoffmann-La Roche Ltd stated that retinal vein occlusion (RVO) is the second most common cause of blindness in the U.S., and affects more than 1 million population with 60 years and older accounting for the majority of the cases.

With the rising aging population and rising prevalence of retinal vein occlusion (RVO) in the U.S., there are continued efforts by market leaders to launch novel therapies in the North America region.

For instance, in October 2023, the U.S. Food and Drug Administration (FDA) approved Vabysmo for the treatment of retinal vein occlusion. Vabysmo (faricimab-svoa) is the novel anti-vascular endothelial growth factor developed by F. Hoffmann-La Roche Ltd.

All these factors stated above are significant contributors to the region's dominance in the global retinal vein occlusion (RVO) market.

Competitive Landscape

The major global players in the Retinal vein occlusion (RVO) market are Bayer AG, Regeneron Pharmaceuticals Inc., F. Hoffmann-La Roche Ltd, Teva Pharmaceutical Industries Ltd., and AbbVie. among others.

Emerging Players

The emerging players in the Retinal vein occlusion (RVO) market include Sunshine Guojian Pharmaceutical (Shanghai)Co.,Ltd., KODIAK SCIENCES INC., and TAIWAN LIPOSOME CO., LTD. among others.

Key Developments

• In December 2024, Regeneron Pharmaceuticals, Inc. published the phase 3 clinical trial results for EYLEA HD (aflibercept) Injection 8 mg for the treatment of patients with macular edema following retinal vein occlusion (RVO), including those with central, branch and hemiretinal vein occlusions. The study met its primary end-point of improving vision in the subject population.
• In July 2024, F. Hoffmann-La Roche Ltd announced that the European Commission (EC) approved Vabysmo (Faricimab) for the treatment of visual impairment due to macular edema secondary to retinal vein occlusion (RVO).
• Why Purchase the Report?
• Pipeline & Innovations: Reviews ongoing clinical trials, and Type pipelines, and forecasts upcoming pharmaceutical advancements.
• Type Performance & Market Positioning: Analyzes Type performance, market positioning, and growth potential to optimize strategies.
• Real-world Evidence: Integrates patient feedback and data into drug-type development for improved outcomes.
• Physician Preferences & Health System Impact: Examines healthcare provider behaviors and the impact of health system mergers on adoption strategies.
• Market Updates & Industry Changes: Covers recent regulatory changes, new policies, and emerging technologies.
• Competitive Strategies: Analyzes competitor strategies, market share, and emerging players.
• Pricing & Market Access: Reviews pricing models, reimbursement trends, and market access strategies.
• Market Entry & Expansion: Identifies optimal strategies for entering new markets and partnerships.
• Regional Growth & Investment: Highlights high-growth regions and investment opportunities.
• Supply Chain Optimization: Assesses supply chain risks and distribution strategies for efficient Type delivery.
• Sustainability & Regulatory Impact: Focuses on eco-friendly practices and evolving regulations in healthcare.
• Post-market Surveillance: Uses post-market data to enhance Type safety and access.
• Pharmacoeconomics & Value-Based Pricing: Analyzes the shift to value-based pricing and data-driven decision-making in R&D.

The global Retinal vein occlusion (RVO) market report would provide approximately 48 tables, 40 figures, and 170 pages.

Target Audience 2023

• Manufacturers: Pharmaceutical, Biotech Companies, Contract Manufacturers, Distributors, Hospitals.
• Regulatory & Policy: Compliance Officers, Government, Health Economists, Market Access Specialists.
• Technology & Innovation: R&D Professionals, Clinical Trial Managers, Pharmacovigilance Experts.
• Investors: Healthcare Investors, Venture Fund Investors, Pharma Marketing & Sales.
• Consulting & Advisory: Healthcare Consultants, Industry Associations, Analysts.
• Supply Chain: Distribution and Supply Chain Managers.
• Consumers & Advocacy: Patients, Advocacy Groups, Insurance Companies.
• Academic & Research: Academic Institutions.